ETFChannel.com
MGNX Description — MacroGenics, Inc

MacroGenics is a biopharmaceutical company focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. Co.'s MARGENZA (margetuximab-cmkb) is a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In addition, Co. has a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, that have been created primarily using its proprietary, antibody-based technology platforms.

Company Name: 
MacroGenics, Inc
Website: 
www.macrogenics.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MGNX: 
32
Total Market Value Held by ETFs: 
$155,060,040.2
Total Market Capitalization: 
$1,682,000,000
% of Market Cap. Held by ETFs: 
9.22%
 ETF   MGNX Weight   MGNX Amount 
 XBI   0.60%   $43,870,326         
 VTI   0.00%   $31,881,740         
 IWM   0.04%   $26,542,189         
 VXF   0.01%   $16,913,272         
 IBB   0.08%   $9,284,202         
 IWO   0.07%   $8,734,615         
 VHT   0.01%   $2,818,799         
 IDNA   0.74%   $2,748,828         
 VTWO   0.04%   $2,604,221         
 LABU   0.32%   $2,162,916         
List of all 32 ETFs holding MGNX »
Quotes delayed 20 minutes

Strong Buy (3.53 out of 4)
53rd percentile
(ranked higher than approx. 53% of all stocks covered)

Analysts Forecast:
MGNX Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding MGNX | MacroGenics, Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.